LY-293558 Eli Lilly & Co

Current Opinion in Investigational Drugs

Volumn 2, Issue 9, 2001, Pages 1273-1278

  Gilron, I ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; LY 293559; LY 377770; UNCLASSIFIED DRUG;

ANALGESIA; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG METABOLISM; DRUG SYNTHESIS; EPILEPSY; HUMAN; MIGRAINE; NONHUMAN; PERIPHERAL VISION; RACEMIC MIXTURE; REVIEW; SEDATION; STRUCTURE ACTIVITY RELATION; VERTIGO; VISUAL IMPAIRMENT;

ANIMALS; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; ISOQUINOLINES; PAIN; RECEPTORS, AMPA; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 0034838021     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Syntheses of 6-oxodecahydroisoquinoline-3-carboxylates. Useful intermediates for the preparation of conformationally defined excitatory amino acid antagonists
2. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinolone-3- carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist
3. The effect of aniracetam and cyclothiazide on the anticonvulsant action of four AMPA antagonists in rodent seizure models
4. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat
5. Characterisation of LY293558 as a stereoselective and competitive AMPA receptor antagonist on rat neocortical slices
6. Stereospecific effects of the competitive and selective AMPA antagonist LY293558 on rat spinal neurones in vivo
7. Effects of LY-293558 and NBQX on glutamate receptor responses in rat cerebellar Purkinje neurones and HEK293 cells expressing the human GLUR6 glutamate receptor
8. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons
9. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl] decahydroisoquinoline-3-carboxylic acid
10. The AMPA antagonist LY293558 improves functional neurological outcome following reversible spinal cord ischemia in rabbits
11. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl] decahydroisoquinoline-3-carboxylic acid (LY293558) and its racemate (LY215490)
12. A selective AMPA antagonist, LY293588, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal
13. (S)-5-Fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors
14. AMPA antagonist LY293558 does not affect the severity of hypoxic-ischemic injury in newborn pigs
15. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
16. The competitive α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to δ or κ opioids
17. Neurotoxin domoic acid produces cytotoxicity via kainate- and AMPA-sensitive receptors in cultured cortical neurones
18. Apoptosis induced via AMPA-selective glutamate receptors in cultured murine cortical neurons
19. Pharmacological discrimination of GluR 5 and GluR 6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(2)H-tetrazole-5-yl)-ethyl]decahyfroisquinoline-3-carboxyli c acid
20. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence
21. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat
22. Decahydroisoquinolines: Novel competitive AMPA/kainate antagonists with neuroprotective effects in global ischemia
23. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischemia
24. LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischemia
25. Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia
26. Neuropharmacology of AMPA and kainate receptors
27. Non-N-methyl-D-aspartate glutamate receptors mediate oxygen-glucose deprivation-induced oligodendroglial injury
28. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse
29. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia
30. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus
31. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area
32. AMPA/kainate antagonist LY-293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans
33. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY-293558 on spontaneous and evoked postoperative pain
34. A double-blind, placebo-controlled study to investigate the efficacy and tolerability of 1.2 mg/kg intravenous LY-293558 versus 6 mg subcutaneous sumatriptan versus placebo in patients with an acute migraine attack
35. Drug development pipeline: LY-293558